- Irbesartan
drugbox
width=200
IUPAC_name = 2-butyl-
3- ["p"-("o"-1"H"-tetrazol-5-ylphenyl)benzyl] -
1,3-diazaspiro [4.4] non-1-en-4-one
CAS_number = 138402-11-6
ATC_prefix = C09
ATC_suffix = CA04
PubChem = 3749
DrugBank = APRD00413
C=25 | H=28 | N=6 | O=1
molecular_weight = 428.53
smiles = CCCCC1=NC2(CCCC2)C(=O)N1Cc1ccc(cc1)c1ccccc1c1n [nH] nn1
bioavailability = 60–80%
metabolism =Hepatic (CYP2C9 )
elimination_half-life = 11–15 hours
excretion =Renal 20%, faecal 65%
licence_EU = Aprovel
licence_US = Irbesartan
pregnancy_category = D (Au)
legal_status = S4 (Au), POM (UK), ℞-only (U.S. )
routes_of_administration = OralIrbesartan (INN) (pronEng|ɜrbəˈsɑrtən) is an
angiotensin II receptor antagonist used mainly for the treatment ofhypertension . Irbesartan was developed by Sanofi Research (now part ofsanofi-aventis ). It is jointly marketed bysanofi-aventis andBristol-Myers Squibb under thetrade name s Aprovel, Karvea, and Avapro.Clinical use
Indications
As with all angiotensin II receptor antagonists, irbesartan is indicated for the treatment of
hypertension . Irbesartan may also delay progression of diabetic nephropathy and is also indicated for the reduction of renal disease progression in patients with type 2 diabetes,cite journal | author=Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group. | title=Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes | journal=N Engl J Med | year=2001 | volume=345 | issue=12 | pages=851–60 | pmid=11565517 | doi=10.1056/NEJMoa011303] hypertension and microalbuminuria (>30 mg/24 hours) or proteinuria (>900 mg/24 hours).Rossi S, editor.Australian Medicines Handbook 2006. Adelaide: Australian Medicines Handbook; 2006. ISBN 0-9757919-2-3]Combination with diuretic
Irbesartan is also available in a combination formulation with a low dose
thiazide diuretic , invariablyhydrochlorothiazide , to achieve an additive antihypertensive effect. Irbesartan/hydrochlorothiazide combination preparations are marketed under similar trade names to irbesartan preparations, including Irda, CoIrda, CoAprovel, Karvezide, Avalide and Avapro HCT.References
ee also
*
Angiotensin II receptor antagonist
Wikimedia Foundation. 2010.